PRTC News and Press, PureTech Health plc From 02/01/23

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer and Eric Elenko, Chief Innovation O...

Rapid advancement of PureTech’s Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral...

Orally administered LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic effect. 1 Allopregnanolone is a natural neurosteroid with proven efficacy that is currently only available as a 60-hour intravenous infusion. Preliminary pharmacodynamic...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 41 st Annu...

Data support the role of galectin-9 in multiple types of leukemia and the ability of anti-galectin-9 antibodies to provide effective anti-tumor activity in these cancers Clinical trial has initiated evaluating LYT-200 as a single agent in acute myeloid leukemia (AML) patients LYT-...

AI vocal biomarker company will use funding to accelerate its commercial growth, expand its platform into new health conditions, and enter new geographies PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biothe...

LYT-310 demonstrated three to fourfold increase in oral bioavailability of CBD compared to unmodified CBD in a preclinical model Oral dosing and potential for improved tolerability could expand therapeutic application of CBD across a wider range of age groups and indications, including bo...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D., ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and ...

Summary During the third quarter of 2022, the Miller Opportunity Equity strategy generated a total return of -4.62% net of fees. Using a three-factor performance attribution model, allocation, and selection effects contributed to the strategy’s outperformance which was part...